Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Dana Chase, MD, FACOG, Assistant Professor, Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix, Arizona, Creighton University School of Medicine at St. Joseph’s Hospital, Omaha, Nebraska
Michelle Shiller, DO, MSPT, Co-Medical Director, Cancer Genetics, Pathologists Biomedical Laboratories/Baylor University Medical Center, Dallas, Texas
Tabetha Sundin, PhD, HCLD(ABB), MB(ASCP)CM, Scientific Director, Molecular Diagnostics and Serology, Sentara Healthcare
The presenters discuss the role of BRCA1/2 mutations in homologous recombination deficiency and carcinogenesis, homologous recombination deficiency as a marker of treatment sensitivity, the testing process for homologous recombination deficiency and BRCA mutations, and the role of BRCA testing in ovarian and breast cancer.
This on-demand webinar originally broadcast on October 23, 2018.
CAP TODAY does not endorse any of the products or services named within.
©2018 AstraZeneca. All rights reserved. US-24014 Last Updated 10/18